CMPH recommends expanded indication for abiraterone in mCRPC … before chemotherapy

According to a summary statement of opinion issued yesterday by the Committee for Medicinal Products for Human Use (CMPH) of the European Mediciens Agency (EMEA), CMPH is recommending an expanded indication for the clinical use of abiraterone acetate in men with metastatic, castration-resistant prostate cancer (mCRPC).

The summary statement of opinion states that abiraterone acetate (Zytiga®) will be indicated, in combination with predisone or prednisolone, for:

  • The treatment of mCRPC in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy (ADT) in whom chemotherapy is not yet clinically indicated, and for
  • The treatment of mCRPC in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen.

The latter of these two indications is the currently approved indication in Europe and the USA. The former is a new indication for earlier use in men who have received no chemotherapy, and is based on data from the second Phase III clinical trial of abiraterone acetate, presented at the annual meeting of the American Society for Clinical Oncology (ASCO) earlier this year.

The final decision of the European Commission to approve this new indication for Zytiga in Europe can be expected within about 60 days.

This decision to recommend and expanded indication for Zytiga in Europe suggests that we may see a similar expansion of the indication for Zytiga in the USA as well … perhaps by the end of the year.

4 Responses

  1. Yea!!

  2. My hope is that known metastasis not be a prerequisite for prescribing abiraterone acetate/Zytiga, and that all men with obvious castration resistant prostate cancer have Zytiga available to attack cells before metastasis is recognized.

  3. Chuck:

    We’re going to need some data to support that idea!

  4. Excellent! I am lucky enough to get Zytiga being a pre-chemo patient. All other anti-androgens had failed. Now in my fouth month, the PSA dropped from 14.35 to 8.44 and is trending down slowly — the best case scenario. Push your provider and insurance company — the drug is helping now. Good luck!

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: